

# Marie J Pierik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/948325/publications.pdf>

Version: 2024-02-01

82  
papers

2,129  
citations

279798  
23  
h-index

254184  
43  
g-index

85  
all docs

85  
docs citations

85  
times ranked

3002  
citing authors

#	ARTICLE	IF	CITATIONS
1	Telemedicine for management of inflammatory bowel disease (myIBDcoach): a pragmatic, multicentre, randomised controlled trial. <i>Lancet, The</i> , 2017, 390, 959-968.	13.7	253
2	Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. <i>Gastroenterology</i> , 2018, 154, 1343-1351.e1.	1.3	240
3	Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDL Cohort. <i>American Journal of Gastroenterology</i> , 2017, 112, 325-336.	0.4	127
4	Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 33-45.	1.3	124
5	Patient-Reported Outcome Measures for Use in Clinical Trials and Clinical Practice in Inflammatory Bowel Diseases: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 648-663.e3.	4.4	93
6	Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 155, 829-843.	1.3	80
7	Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 549-555.	1.3	70
8	Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 637-646.e11.	4.4	67
9	Volatile metabolites in breath strongly correlate with gut microbiome in CD patients. <i>Analytica Chimica Acta</i> , 2018, 1025, 1-11.	5.4	64
10	Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 880-888.	3.7	64
11	Systemic Inflammation in Preclinical Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 161, 1526-1539.e9.	1.3	58
12	Risk factors of work disability in patients with inflammatory bowel disease – A Dutch nationwide web-based survey. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 590-597.	1.3	52
13	Cohort Profile: The Inflammatory Bowel Disease South Limburg Cohort (IBDSL). <i>International Journal of Epidemiology</i> , 2017, 46, e7-e7.	1.9	48
14	Faecal Microbiota Dynamics and their Relation to Disease Course in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1273-1282.	1.3	42
15	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 366.	1.6	40
16	Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. <i>Gut</i> , 2021, 70, 1266-1274.	12.1	40
17	Modulation of Intestinal Epithelial Permeability by Plasma from Patients with Crohn's Disease in a Three-dimensional Cell Culture Model. <i>Scientific Reports</i> , 2019, 9, 2030.	3.3	38
18	Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 699-708.	1.3	36

#	ARTICLE	IF	CITATIONS
19	Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. <i>BMJ Open</i> , 2017, 7, e016695.	1.9	33
20	Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouchâ€‘Anal Anastomosis, Ileostomy and Anti-TNFÎ± Therapy. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 1016-1023.	1.3	30
21	High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score. <i>Digestive Diseases and Sciences</i> , 2017, 62, 465-472.	2.3	29
22	Dietary Intake Pattern is Associated with Occurrence of Flares in IBD Patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1305-1315.	1.3	28
23	Novel Perceived Stress and Life Events Precede Flares of Inflammatory Bowel Disease: A Prospective 12-Month Follow-Up Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 410-416.	1.3	27
24	Disease Activity Patterns of Crohnâ€™s Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 391-400.	1.3	25
25	Vedolizumab for Inflammatory Bowel Disease: Twoâ€‘Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1189-1199.	4.7	24
26	Incidence and Classification of Postcolonoscopy Colorectal Cancers in Inflammatory Bowel Disease: A Dutch Population-Based Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 777-783.	1.3	23
27	Ustekinumab for Crohnâ€™s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1920-1930.	1.3	22
28	Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35â€‘mg once weekly or placebo, concomitant with calcium and vitamin D supplementation. <i>Gut</i> , 2014, 63, 1424-1430.	12.1	21
29	Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease. <i>Annals of Surgery</i> , 2021, 273, 557-563.	4.2	21
30	Pooled Resequencing of 122 Ulcerative Colitis Genes in a Large Dutch Cohort Suggests Population-Specific Associations of Rare Variants in MUC2. <i>PLoS ONE</i> , 2016, 11, e0159609.	2.5	21
31	Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1704-1718.	4.4	19
32	A comparative analysis of tioguanine versus lowâ€‘dose thiopurines combined with allopurinol in inflammatory bowel disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1076-1086.	3.7	18
33	Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, jjw160.	1.3	17
34	Inter-kingdom relationships in Crohnâ€™s disease explored using a multi-omics approach. <i>Gut Microbes</i> , 2021, 13, 1930871.	9.8	16
35	Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohnâ€™s Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 947-954.e2.	4.4	15
36	Impaired Gastric Cancer Survival in Patients with Inflammatory Bowel Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 431-440.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2015-2026.	1.9	14
38	Risk of impaired nutritional status and flare occurrence in IBD outpatients. <i>Digestive and Liver Disease</i> , 2019, 51, 1265-1269.	0.9	14
39	Interleukin-28A induces epithelial barrier dysfunction in CD patient-derived intestinal organoids. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G689-G699.	3.4	14
40	Better survival of renal cell carcinoma in patients with inflammatory bowel disease. <i>Oncotarget</i> , 2015, 6, 38336-38347.	1.8	14
41	Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era—Results from the Dutch Population-Based IBDL Cohort. <i>American Journal of Gastroenterology</i> , 2018, 113, 384-395.	0.4	12
42	Diet Quality and Dietary Inflammatory Index in Dutch Inflammatory Bowel Disease and Irritable Bowel Syndrome Patients. <i>Nutrients</i> , 2022, 14, 1945.	4.1	11
43	Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1464-1473.	1.3	10
44	The faecal scent of inflammatory bowel disease: Detection and monitoring based on volatile organic compound analysis. <i>Digestive and Liver Disease</i> , 2020, 52, 745-752.	0.9	9
45	P503 Two year experience with vedolizumab in inflammatory bowel disease patients: results of the ICC case series, a nationwide prospective observational cohort study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S363-S364.	1.3	8
46	Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events. <i>International Journal of Colorectal Disease</i> , 2020, 35, 2331-2338.	2.2	8
47	Genetic Risk Scores Identify Genetic Aetiology of Inflammatory Bowel Disease Phenotypes. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 930-937.	1.3	8
48	Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110125.	3.2	7
49	Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 999-1012.	3.7	7
50	Off-label prescriptions of drugs used for the treatment of Crohn's disease or ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1293-1300.	3.7	6
51	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. <i>New England Journal of Medicine</i> , 2020, 382, 92-94.	27.0	6
52	Ambient air quality as risk factor for microscopic colitis – A geographic information system (GIS) study. <i>Environmental Research</i> , 2019, 178, 108710.	7.5	4
53	Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1470-1473.	1.3	4
54	The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e102-e107.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Prediction of Inflammatory Bowel Disease Course Based on Fecal Scent. <i>Sensors</i> , 2022, 22, 2316.	3.8	4
56	Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1060-1067.	1.9	3
57	Vulvar and vaginal neoplasia in women with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020, 52, 149-155.	0.9	3
58	OC-047...Epigenetic alterations at diagnosis predict susceptibility, prognosis and treatment escalation in inflammatory bowel disease " ibd character. , 2017, , .		2
59	Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1885-1897.	1.3	2
60	On the External Validity of Epidemiologic Data from Hospital-based IBD Cohorts. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1372-1373.	1.3	1
61	OP25 Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S016-S018.	1.3	1
62	Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure"getting closer to the truth. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1255-1256.	3.7	1
63	P398 Effect of Intravenous versus Oral Iron Therapy on Physical Fitness and Haemoglobin in Paediatric IBD Patients with Anaemia. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S407-S408.	1.3	1
64	Remote Monitoring of Inflammatory Bowel Disease: What Kind of Patient-Reported Questionnaires Should We Use?. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 869-870.	1.3	1
65	Patient-reported continuous clinical response to golimumab in adults with moderately to severely active ulcerative colitis: results from GO OBSERVE, a real-world European observational study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 646-654.	1.6	1
66	AODTH-008...Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in inflammatory bowel diseases: ibd character study. , 2017, , .		0
67	DOP049 Inflammatory dyskinesia: defects of NF- $\kappa$ B dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, S55-S56.	1.3	0
68	P858 Crohn's disease is characterised by a fungal dysbiosis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S550-S551.	1.3	0
69	Scientific Business Abstracts of the 112th Annual Meeting of the Association of Physicians of Great Britain and Ireland. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 920-924.	0.5	0
70	DOP034 Assessment of direct healthcare cost drivers of Crohn's disease in a Dutch population-based cohort study shows a major shift. <i>Journal of Crohn's and Colitis</i> , 2018, 12, S054-S055.	1.3	0
71	P702 Off-label drug use in patients with inflammatory bowel disease: a national survey among tertiary care centres. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S472-S472.	1.3	0
72	P784 Prevalence of cervical dysplasia in women with inflammatory bowel disease: data from the Parelinoer Institute (PSI) and PALGA database (PAP-IBD study). <i>Journal of Crohn's and Colitis</i> , 2019, 13, S513-S513.	1.3	0

#	ARTICLE	IF	CITATIONS
73	P340 Comorbidity is associated with safety outcomes in vedolizumab- and ustekinumab-treated inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2020, 14, S326-S327.	1.3	0
74	P450 Thioguanine and low dose thiopurines and allopurinol are both safe options after failure of conventional thiopurines: a comparative analysis of two multicentre cohorts. Journal of Crohn's and Colitis, 2020, 14, S404-S405.	1.3	0
75	Letter: ustekinumab's effectiveness compared with vedolizumab in Crohn's disease—what about mucosal healing and biomarkers? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 52, 753-754.	3.7	0
76	Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial. BMJ Open, 2021, 11, e042885.	1.9	0
77	P286 Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis, 2021, 15, S319-S320.	1.3	0
78	P140 Predicting Non-Responsiveness to Iron Therapy in Anaemic Children with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, S226-S226.	1.3	0
79	OMO-1—Epigenetic alterations in IBD: defining geographical, genetic, and immune-inflammatory influences on the circulating methylome. , 2021, , .		0
80	P595 Validation of a predictive algorithm for thiopurine induced hepatotoxicity in IBD patients. Journal of Crohn's and Colitis, 2022, 16, i530-i531.	1.3	0
81	P526 Measurement of thiopurine metabolites concentrations after one week of treatment does not predict treatment failure in Inflammatory Bowel Disease patients. Journal of Crohn's and Colitis, 2022, 16, i480-i481.	1.3	0
82	P317 Ustekinumab Trough Concentrations Associated with Biochemical Outcomes in Patients with Crohn's Disease. Journal of Crohn's and Colitis, 2022, 16, i340-i341.	1.3	0